Navigation

MS treatment lifts Serono sales

Serono is Europe's leading biotechnology company Keystone Archive

Europe's biggest biotechnology company, Serono, has reported a 5.2 per cent rise in net income for 2001 with sales driven by its flagship multiple sclerosis treatment, Rebif.

This content was published on February 13, 2002 - 10:10

The Geneva-based company's net income was up to $316.7 million (SFr534.6), with Rebif sales up 54.1 per cent to reach $338.4 million. Sales as a whole increased 15 per cent to $1.249 billion.

The figures were in line with analysts expectations but there was further good news as the company announced expected the US Food and Drug Administration to reach a decision on Rebif in March. A positive decision would end the US marketing exclusivity of the rival MS drug, Avonex, made by Biogen.

Serono shares jumped by more than 5 per cent in early trading on Wednesday.

The company also reported a 14.7 per cent growth in its fertility treatment, Gonal-F. But it said further expansion in this area could be slower because many prospective patients have delayed the start of in vitro fertilisation treatment in the wake of the September 11 attacks on the US.

Serono has proposed a cash dividend of SFr6.25 per share.

swissinfo with agencies

This article was automatically imported from our old content management system. If you see any display errors, please let us know: community-feedback@swissinfo.ch

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

Share this story

Change your password

Do you really want to delete your profile?